# Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer

> **NCT01271166** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 10 (actual)

## Conditions studied

- Advanced Colorectal Cancer

## Interventions

- **DRUG:** Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab

## Key facts

- **NCT ID:** NCT01271166
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-10
- **Primary completion:** 2009-08
- **Final completion:** —
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2011-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01271166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01271166, "Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01271166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*